🧪
野崎 千尋
岐阜生まれ。工学修士（京都工繊大）、薬学博士（星薬大）。フランス国立IGBMC、ドイツ国立ボン大学IMP、東京理科大学生命医科学研究所を経て2020年より現職。専門は疼痛・神経炎症・神経免疫学・神経薬理学。「我々の身体からカンナビノイド受容体が無くなったらどうなるのか？」をテーマに、カンナビノイドが難治性疼痛・肥満・アレルギーといった様々な慢性疾患をどう調節するか、その機序解明を目指した研究を行っている。
Born in Gifu. Holds a Master's in Engineering from Kyoto Institute of Technology and a Doctorate in Pharmacy from Hoshi University. After roles at the French National IGBMC, Germany's Bonn University IMP, and Tokyo University of Science's Institute of Life and Medical Sciences, he assumed his current position in 2020. His areas of expertise include pain, neuroinflammation, neuroimmunology, and neuropharmacology. Centering his research on the question, "What would happen if cannabinoid receptors were removed from our bodies?", he is investigating how cannabinoids regulate various chronic diseases such as intractable pain, obesity, and allergies, aiming to elucidate their mechanisms of action.